New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2013
07:06 EDTCHD, PFE, PGMore vitamin deals expected, WSJ reports
Procter & Gamble (PG), Pfizer (PFE) and Arm & Hammer (CHD) owner Church & Dwight Co. all acquired makers of dietary supplements last year. More deals are expected, as companies bet baby boomers and rising health-care costs will drive demand for products, reports the Wall Street Journal.Reference Link
News For PG;PFE;CHD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 27, 2015
07:16 EDTPFEPfizer drops 2.7% after FY15 outlook miss expectations
Subscribe for More Information
07:15 EDTPGProcter & Gamble sees significant negative sales, EPS impact in 2H from forex
P&G net sales growth is now expected to be lower versus the prior fiscal year in the range of -3% to -4%, including a negative five point headwind from foreign exchange and a one point impact from minor brand divestitures. Including currency impacts, Core EPS is now expected to be in the range of in-line to down low-single digits versus prior year Core EPS of $4.09. All-in GAAP diluted net earnings per share are now expected to be down in the mid-teens range versus the prior year. Consensus for FY15 EPS/revenue $4.15/$79.13B.
07:14 EDTPGProcter & Gamble backs FY15 organic sales, currency-neutral core EPS outlook
P&G maintained its organic sales growth and currency-neutral core earnings per share growth guidance ranges for fiscal year 2015, but the company expects significant negative sales and earnings impacts from foreign exchange in the second half of its fiscal year. The company maintained its guidance for organic sales growth in the low-to-mid single digit range. Net sales growth is now expected to be lower versus the prior fiscal year in the range of -3% to -4%, including a negative five point headwind from foreign exchange and a one point impact from minor brand divestitures. P&G maintained its outlook for currency-neutral core earnings per share growth in the double-digits. Including currency impacts, Core EPS is now expected to be in the range of in-line to down low-single digits versus prior year Core EPS of $4.09. All-in GAAP diluted net earnings per share are now expected to be down in the mid-teens range versus the prior year. This includes approximately 67c per share of non-core charges, primarily from 20c per share of non-core restructuring charges and 58c of impairment charges, which are partially offset by approximately 14c of earnings from discontinued Batteries and Pet Care operations.
07:07 EDTPFEPfizer sees FY15 adjusted EPS $2.00-$2.10, consensus $2.18
Subscribe for More Information
07:03 EDTPGProcter & Gamble reports Q2 core EPS $1.06, consensus $1.13
Reports Q2 revenue $20.16B, consensus $20.62B. Organic sales grew 2% for the quarter.
07:01 EDTPFEPfizer reports Q4 adjusted EPS 54c, consensus 53c
Reports Q4 revenue $13.1B, consensus $12.9B.
January 26, 2015
16:15 EDTPFEPfizer commits to lower price for Prevenar 13 in developing countries
Subscribe for More Information
15:40 EDTPFE, PGNotable companies reporting before tomorrow's open
Subscribe for More Information
15:35 EDTPGProcter & Gamble January weekly 89 straddle priced for 2.4% movement into Q2
Subscribe for More Information
14:04 EDTPGProcter & Gamble technical comments before earnings
Subscribe for More Information
13:29 EDTPFEEarnings Preview: Pfizer set to report Q4 results as generics impact Celebrex
Subscribe for More Information
January 23, 2015
16:08 EDTPFETeva volatility elevated, Pfizer approached late last year, Bloomberg says
Teva (TEVA) overall option implied volatility of 25 compares to its 26-week average of 23 according to Track Data, suggesting large price movement into Pfizer (PFE) approach late last year, Bloomberg says.
16:04 EDTPFETeva rebuffed Pfizer approach late last year, Bloomberg says
Subscribe for More Information
08:18 EDTPGProcter & Gamble added to US Focus List at Credit Suisse
Credit Suisse added Procter & Gamble (PG) to the US Focus LIst and removed Colgate-Palmolive (CL), Chevron (CVX) and Williams (WMB).
January 22, 2015
14:28 EDTPGProcter & Gamble volatility elevated into Q2 and outlook
Procter & Gamble January weekly call option implied volatility is at 20, February is at 14, March is at 12; compared to its 26-week average of 14 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on January 27.
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
January 21, 2015
12:35 EDTPGProcter & Gamble's David Taylor likely candidate to succeed CEO, Fortune says
After a recent promotion to lead the beauty business at Proctor & Gamble by CEO A.G. Lafley, David Taylor, who currently runs the global health and grooming business division, now running two of the four business units, appears as the lead candidate to succeed CEO Lafley when he retires from the company, Fortune reports. Reference Link
12:30 EDTPFEGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
10:01 EDTCHDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:39 EDTCHDChurch & Dwight downgraded to Neutral from Buy at UBS
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use